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Objective/background: Membranoproliferative glomerulonephritis (MPGN) is a common extra-
medullary renal presentation in chronic lymphocytic leukemia (CLL) and can present with
either a frank renal failure or proteinuria. One of its etiologies has been attributed to a para-
neoplastic, immune complex phenomenon occurring in CLL. Although there is no standard of
care in such patients, use of anti-CD20 monoclonal antibodies like rituximab have been used
before in such patients with variable responses. Obinutuzumab is a novel, type II,
immunoglobulin-G1 monoclonal antibody with a higher efficacy than rituximab and has an
established safely profile in patients with comorbidities and poor renal functions. There are
no such reported cases of MPGN in CLL being treated with obinutuzumab.
Methods: We used the standard doses of obinutuzumab in our elderly patient (78-year-old
woman) with high-risk CLL due to an underlying TP53 mutation, along with a MPGN-related
acute renal failure.
Results: The patient achieved complete remission after six cycles of obinutuzumab; however,
she remained positive for minimal residual disease on flow cytometry. Her renal function
improved completely, suggesting a complete response of her underlying MPGN., Houston,
onic lym-
5.001
2 P. Jain et al.
Please cite this article in press as: Jain
phocytic leukemia: Response to obinuConclusion: Obinutuzumab has an established safety profile in patients with CLL, but our case
is the first reported case of a paraneoplastic, immune complex-mediated MPGN in CLL being
treated with obinutuzumab. Obinutuzumab should be explored as a potential option in patients
with CLL and MPGN.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Chronic lymphocytic leukemia (CLL) is the most common
leukemia in the United States [1,2]. Most patients are
asymptomatic at the time of diagnosis, and do not require
CLL-directed treatment. Progressive adenopathy/organo-
megaly and cytopenias are common reasons to initiate
treatment for CLL. The incidence of extramedullary/extra-
nodal organ involvement is low [3]. Ratterman et al. [3]
identified 192 extramedullary/extranodal cases of CLL
reported between 1975 and 2012 in literature. Skin (33%)
and the central nervous system (27%) were the most com-
monly involved sites. Involvement of genitourinary and
gynecological sites was rare, constituting less than 10% of
the total reported cases. A recent study from the group at
the Mayo Clinic reported renal insufficiency (serum crea-
tinine P1.5 mg/dL) in 153 (7.5%) patients of CLL, with
patients presenting with either a nephrotic syndrome or
with an acute renal failure [4]. Membranoproliferative
glomerulonephritis (MPGN), interstitial infiltration by CLL
cells, minimal change disease, and thrombotic microan-
giopathy constitute the most commonly reported renal
pathologies in patients with CLL and renal involvement
[5,6]. Here, we report a patient with CLL with extramedul-
lary involvement of the kidneys in the form of MPGN and
presenting with acute renal failure. The patient received
six cycles of obinutuzumab (type II CD20-monoclonal anti-
body) with normalization of her renal function. To our
knowledge, this is the first case of CLL with MPGN that
was treated with obinutuzumab.
Patient profile
A healthy 78-year-old woman was noted to have leukocyto-
sis on a routine annual medical evaluation in 2002. Her
white blood cell count was 18.6 K/lL with lymphocytosis.
Hemoglobin and platelet count were normal. She was
advised clinical observation given her early stage CLL. She
remained asymptomatic until December 2014 when she
started to develop fatigue. She also started to have dark-
colored urine along with a decreasing urine output over a
period of 2 weeks. She was evaluated at an outside hospital
on January 15, 2015, and was found to have an oliguric renal
failure with a creatinine level of 8.1 mg/dL. Her white blood
cell count was 9.2 K/lL, hemoglobin 8.9 g/dL, and her pla-
telet count was 154 K/lL. She was found to have proteinuria
(1980 mg/24 h) with low levels of complement 3 and 4.
Antinuclear antibody levels were normal. Ultrasonography
of the kidneys excluded an obstructive uropathy. She under-
went multiple sessions of hemodialysis. A renal
biopsy revealed features of monoclonal gammopathy withP et al., Membranoproliferative glo
tuzumab ..., Hematol Oncol Stemmembranous glomerulonephritis (Fig. 1A–E). A bone mar-
row biopsy showed a mildly hypercellular bone marrow with
50% cellularity with trilineage hematopoiesis and CLL/small
lymphocytic lymphoma involving 40% of the cellularity. Flow
cytometry (FCM) revealed a clonal population of small cells
with CD19+, CD20dim+, CD5+, CD10-,CD38-, CD23+, FMC7-,
kappa-, and lambda-immunophenotype. Positron emission
tomography–computed tomography scan showed mildly
prominent lymph nodes in the cervical, axillary, and ingu-
inal areas. She received high-dose steroids for 4 weeks to
treat her MPGN. Her renal function stabilized with a
creatinine level of around 3.5–4 mg/dL, and she was able
to cease dialysis. She was then referred to our center for
further management.
Clinical findings
At presentation to our hospital, the patient complained of
extreme fatigue and was wheelchair bound. She had no
other comorbidities. Physical examination was significant
for <1-cm lymph nodes in the cervical and axillary area.
Peripheral smear showed a normocytic normochromic ane-
mia with mild anisopoikilocytosis, leukocytosis with mainly
atypical lymphocytes, and numerous smudge cells. Her
white blood cell count was 19.4 K/lL, with an absolute lym-
phocyte count of 17.6 K/lL, hemoglobin 9.2 g/dL, and pla-
telet count of 308 K/lL. Other parameters at presentation
included a lactate dehydrogenase level of 668 IU/L, blood
urea nitrogen of 47 mg/dL, and a creatinine level of
3.94 mg/dL.
Diagnosis
Considering her unusual presentation, we repeated the bone
marrow examination. Bone marrow (Fig. 1F) and FCM done
on February 02, 2015, were confirmatory of CLL. Cytogenet-
ics showed a normal female karyotype. CLL fluorescence in
situ hybridization panel was positive for deletion 13q.
Additional prognostic markers included a b2-microglobulin
of 13.5 mg/L and a mutated IGVH gene. CD38 was not
expressed. Next-generation sequencing performed for the
detection of somatic mutations revealed two TP53 muta-
tions. The first TP53 was a missense mutation (c.641 A>G
p.H214R) in exon 6 and the second TP53mutation was a pre-
viously unknown, splice mutation (c.672+1G>A). Serum
immunoglobulin levels were normal. A urine analysis showed
multiple red blood cells, white blood cells, and hyaline
casts, suggestive of a nephritic syndrome. Serum protein
electrophoresis and immunofixation studies excluded
multiple myeloma. Hepatitis B and C viral serology was also
negative. There was no evidence of cryoglobulinemia. Amerulonephritis and acute renal failure in a patient with chronic lym-
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Fig. 1 (A) Hematoxylin and eosin showing diffuse endocapillary and mesangial hypercellularity, focal red blood cell casts and
increased small round lymphocytes; (B–E) showing diffuse capillary granular deposits of complement 3, immunoglobulin-G, kappa,
and lambda, respectively; (F) bone marrow biopsy showing nodular and interstitial small lymphocytic infiltrates.
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of a type 1 acute MPGN on electron microscopy (Fig. 1A–E).
Immunofluorescence studies showed diffuse granular depos-
its of C3, immunoglobulin-G, and kappa light chains. We
considered MPGN as a paraneoplastic renal manifestation
of CLL, and initiated her on obinutuzumab monotherapy
on March 11, 2015. She tolerated obinutuzumab well with
no infusion reactions and within a month her creatinine
improved from 3.2 mg/dL to 1.0 mg/dL (Fig. 2). She
received a total of six cycles of obinutuzumab as per the
approved dosing schedule. There was significant improve-
ment in all hematological parameters with normalization
of white blood cell count, absolute lymphocyte count, and
hemoglobin. At her last follow up on September 28, 2015,
she had a normal renal function, and was in complete remis-
sion with a positive minimal residual disease status using
FCM.0
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Fig. 2 Improvement in creatinine (Cr) levels with obinutuzumab.
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MPGN is a rare manifestation in patients with CLL and it is
quite heterogeneous in presentation [5,6]. Its clinical profile
may vary from an asymptomatic hematuria or proteinuria, a
classical acute nephritic or a nephrotic syndrome, acute
renal failure, or even with features of chronic kidney dis-
ease [7]. The pathogenesis of MPGN could result from an
immune-complex mediated phenomenon or a C3 mediated
complement activation [7,8]. CLL is known to cause an
immune-mediated MPGN as a result of localization of the
antigen–antibody complex in the glomeruli which reflects
as granular deposits on electron microscopy of the renal
biopsy [9]. These antibodies are usually polyclonal and stain
for both kappa and lambda light chain, as seen in the pre-
sent case. Steroids and cyclophosphamide have shownab
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4 P. Jain et al.responses in patients with idiopathic MPGN [8,9].
Rituximab, a type I CD20-monoclonal antibody has also been
shown to be effective in patients with MPGN [5,9]. In an
open label trial of six patients with MPGN (six idiopathic,
two with cryoglobulinemic MPGN), use of rituximab caused
a significant improvement in the proteinuria along with a
suppression in the peripheral B cells, though the creatinine
clearance did not change significantly [10]. In a retrospec-
tive study by Guiard et al. [11] on 26 patients with noncryo-
globulinemic glomerulonephritis and monoclonal
immunoglobulin-deposits [MPGN (n = 5) and membranous
glomerulopathy (n = 2)], rituximab was administered as
4-weekly doses of 375 mg/m2 in seven patients [MPGN
(n = 5) and membranous glomerulopathy (n = 2)] [11]. One
patient received two maintenance doses, 8 months and
14 months after the initial treatment. A complete response
(CR) of the nephrotic syndrome (n = 22) was seen in five
patients receiving rituximab (n = 7) after a mean delay of
9 months (range, 4–24 months). Two patients showed a par-
tial response with a significant reduction of proteinuria,
serum albumin, and stabilization of the renal functions.
Only one patient relapsed after 44 months of therapy. Due
to severe renal dysfunction, rituximab was not administered
again in that patient.
Obinutuzumab is a novel type II glycoenginered anti-CD20
monoclonal antibody inducing higher antibody dependent
cellular cytotoxicity than type I antibodies such as rituximab
[12–14]. Obinutuzumab–chlorambucil combination in
patients with CLL have shown higher rates of CR (20.7% vs.
7.0%) and a superior progression-free survival (hazard ratio,
0.39; p < .001) in comparison with rituximab–chlorambucil
(CLL11 trial) [15]. Although the obinutuzumab–chlorambucil
combination arm did have a higher incidence of infusion-
related reactions and neutropenia in comparison with the
rituximab–chlorambucil arm, the overall risk of infection
was not increased [15]. Additionally, dose modifications
for obinutuzumab are not considered necessary even in
patients with extreme renal function, although the data
are limited [14–16]. As our patient had a high-risk CLL due
to the presence of a TP53 mutation, we considered treating
her with obinutuzumab. She received six cycles of obinu-
tuzumab, and achieved a minimal residual disease-positive
CR. To our knowledge, this is the first report of a patient with
CLL and renal failure due to MPGN treated successfully with
obinutuzumab. Use of obinutuzumab led to a rapid recovery
of the underlying renal dysfunction in our patient. Notably,
there were no infusion reactions or prolonged cytopenia sec-
ondary to obinutuzumab.Conflicts of interest
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